An interventional study of Tosoo Axora and Tosoo Axora in Parkinson Disease and REM Sleep Behavior Disorder (iRBD), sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by University of Zurich · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.
Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 14th largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2026, is one of 49 with no phase, reaches primary completion later than 32 of the 33 other live ones, and was the 79th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–75
Siegward -M. Elsas · Sites in Switzerland
Ages 50–79
University of Zurich · Sites in Switzerland
Ages 18+
Alain Kaelin · Sites in Switzerland
Ages 50–80
Julien Bally · Sites in Switzerland
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 30 across the 67 interventional studies, 64 across the 18 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 85 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
University of Zurich has 8 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Parkinson Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831500Julien BallyFeasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | 2026-11 |
| NCT07485218University of Applied Sciences and Arts of Southern SwitzerlandMultidimensional Assessment of Fatigability in Older Adults Living in Southern Switzerland and Elderly With Parkinson's Disease | 2026-12 |
| NCT06608875University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT05765110Insel Gruppe AG, University Hospital BernSPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease | 2026-12-31 |
| NCT07802509Klinik ValensDoes Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease? | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 85 studies in Parkinson Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests whether enhancing deep sleep with gentle sounds at night can slow progression in people with iRBD or early Parkinson's disease. Participants wear a sensor headband and headphones for 18 months. Four assessments including mobility, memory, imaging (PET/MRI), lumbar puncture, and blood tests are assessed.
Many people with REM sleep behavior disorder (iRBD) develop Parkinson's disease or similar conditions over the years. To date, there is no effective method to prevent this transition. Animal experiments and observational studies in patients and older adults indicate that deeper sleep is associated with a slower progression of brain changes. In this study, we are now investigating whether enhancement of deep sleep using sounds during sleep can influence the progressive brain changes in iRBD or early Parkinson's disease.
Participants wear a headband with sensors and headphones for 18 months, which plays gentle sounds during sleep to enhance deep sleep. In addition, four examinations are carried out, including tests of mobility, memory, imaging (PET/MRI), a lumbar puncture, and blood sampling. Two of the examinations will take place at the University Hospital of Zurich, and two more can also be carried out at home if desired.
The aim is to investigate whether enhancement of deep sleep can help slow the progression of iRBD or early-stage Parkinson's disease. The study is double-blind and controlled, which means that neither the participants nor the researchers know who is receiving the active treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Further inclusion criteria are:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nightly enhancement of slow waves through Phase Targeted Auditory Stimulation (PTAS) over 18 months.
Device: Tosoo Axora
Nightly application of tones that will be applied in a non-PTAS manner, resulting in no enhancement of slow waves over 18 months.
Device: Tosoo Axora
Phase Targeted Auditory Stimulation (PTAS) will be applied through integrated headphones with a portable EEG device when non-rapid-eye-movement (NREM) sleep is detected during the night.
Also known as: PTAS Intervention (Verum)
Auditory stimuli will be delivered during the night through integrated headphones with a portable EEG device in a non-PTAS manner.
Also known as: PTAS Intervention (Sham)
Presynaptic Dopaminergic Integrity
Striatal dopaminergic function as measured by high-resolution 18F-Fluorodopa (18F-DOPA)-PET imaging.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
MDS-UPDRS Part III Score
Motor symptom severity assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III), a clinician-rated examination of motor signs.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Purdue Pegboard Test Score
Manual dexterity and fine motor coordination assessed by total score on the Purdue Pegboard Test.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Alternate Finger Tapping Test
Motor speed and coordination assessed by performance on the Alternate Finger Tapping Test.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
UPDRS I.1 (subjective cognition)
Patient-reported cognitive experiences of daily living assessed by MDS-UPDRS Part I, Item 1.1.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Montreal Cognitive Assessment (MoCA) Score
Global cognitive function assessed by MoCA total score.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)
Trail Making Test Part A
Processing speed and attention assessed by time to completion on Trail Making Test Part A.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Trail Making Test Part B
Executive function assessed by time to completion on Trail Making Test Part B.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Digit Span Forward
Attention assessed by Digit Span Forward from the Wechsler Adult Intelligence Scale.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Digit Span backward
Working memory assessed by Digit Span Backward from the Wechsler Adult Intelligence Scale
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Stroop Test
Executive function and inhibitory control assessed by Stroop Color-Word Test.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Verbal Fluency - Semantic
Semantic verbal fluency assessed by category fluency task.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Benton Judgment of Line Orientation (BJLO)
Visuospatial function assessed by Benton Judgment of Line Orientation test.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
LPS-4 Logical Reasoning
Logical reasoning assessed by Leistungsprüfsystem subtest 4.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Rey-Taylor Complex Figure Test - Copy
Visuoconstruction assessed by copy trial of the Rey-Taylor Complex Figure Test.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Rey-Taylor Complex Figure Test - Recall
Visual memory assessed by delayed recall of the Rey-Taylor Complex Figure Test.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
California Verbal Learning Test (CVLT)
Verbal learning and memory assessed by California Verbal Learning Test.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Verbal Fluency - Phonemic
Phonemic verbal fluency assessed by letter fluency task.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Boston Naming Test (BNT)
Naming and language function assessed by Boston Naming Test
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
WAIS Similarities
Verbal abstract reasoning assessed by similarities subtest from the Wechsler Adult Intelligence Scale
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: Home Sleep EEG - Sleep Microstructure
NREM sleep oscillatory activity and microstructural features measured by portable EEG device (Tosoo Axora) during nightly use, including but not limited to slow wave activity, sleep spindles, and their temporal dynamics.
Time frame: Continuous over 18 months
Exploratory Outcome: Home Sleep EEG - Sleep Macrostructure
Sleep architecture and derived metrics measured by portable EEG device (Tosoo Axora) during nightly use, including sleep stage distribution, sleep continuity, and sleep timing parameters.
Time frame: Continuous over 18 months
Exploratory Outcome: MRI
Neuroanatomical and vascular markers assessed by brain MRI, including structural imaging, phase-contrast imaging, arterial spin labeling, and related sequence
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: 18F-DOPA PET - Exploratory Parameters
Exploratory PET parameters including visual assessment of striatal uptake patterns, influx constant (Ki), and F-DOPA distribution beyond predefined regions of interest
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: Psychomotor Vigilance Task (PVT)
Sustained attention and reaction time assessed by the Psychomotor Vigilance Task.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Exploratory Outcome: Sustained Attention to Response Task (SART)
Vigilance and response inhibition assessed by the Sustained Attention to Response Task.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Exploratory Outcome: Glucose Metabolism
Glucose metabolism (HbA1c, glycosylated hemoglobin) will be assessed to explore glucose tolerance and control through a simple blood draw.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome - Polysomnography - Sleep Architecture
Sleep macrostructure including total sleep time, sleep efficiency, and sleep stage distribution assessed by in-laboratory polysomnography.
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: Polysomnography - REM Sleep Without Atonia
REM sleep without atonia (RWA) quantified as percentage of REM sleep with elevated muscle tone on polysomnography.
Time frame: assessed at Baseline and Closeout (18 months)
Exploratory Outcome: Actigraphy - Sleep-Wake Patterns
Sleep-wake rhythm including total sleep time, sleep efficiency, and rest-activity patterns assessed by wrist actigraphy over 2-week periods.
Time frame: assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each
Exploratory Outcome: Sleep Diary
Self-reported sleep timing, duration, and quality recorded daily over 2-week periods.
Time frame: Assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each
Exploratory Outcome: Sleep Quality- Visual Analog Scale -
Subjective sleep quality assessed by Visual Analog Scale.
Time frame: assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each
Exploratory Outcome - Karolinska Sleepiness Scale (KSS)
Subjective daytime sleepiness assessed by Karolinska Sleepiness Scale.
Time frame: assessed before/after each visit (Baseline, after 6 months, after 12 months, Closeout (18 months)) for 2 weeks each
Exploratory Outcome: Retinal Nerve Fiber Layer Thickness (RNFL)
Retinal nerve fiber layer thickness measured by optical coherence tomography (OCT)
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: Ganglion Cell-Inner Plexiform Layer Thickness (GCIPL)
Ganglion cell-inner plexiform layer thickness measured by optical coherence tomography (OCT)
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: Macular Vessel Density (MVD)
Macular vessel density measured by optical coherence tomography angiography (OCT-A)
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: Non-Motor Symptoms Scale (NMSS)
Non-motor symptom severity and frequency assessed by the Non-Motor Symptoms Scale, a 30-item questionnaire covering nine symptom dimensions
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Exploratory Outcome: Epworth Sleepiness Scale (ESS)
Daytime sleepiness assessed by the Epworth Sleepiness Scale (8-item self-report questionnaire)
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Exploratory Outcome: Parkinson's Disease Sleep Scale-2 (PDSS-2)
Sleep disturbances assessed by the PDSS-2, a 15-item self-administered questionnaire covering motor problems at night, PD-specific nocturnal symptoms, and disturbed sleep.
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Exploratory Outcome: Ikelos Rating Scale
RBD symptom severity assessed by the Ikelos Rating Scale, evaluating frequency and severity of REM sleep behavior disorder
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Exploratory Outcome: Exploratory Outcome: EQ-5D-5L
Health-related quality of life assessed by the EQ-5D-5L questionnaire, covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, plus visual analogue scale
Time frame: assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout))
Exploratory Outcome: Blood Biomarkers
Neurodegenerative and inflammatory markers measured in blood, including neurofilament light chain (NfL) and alpha-synuclein
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Exploratory Outcome: CSF Biomarkers
Neurodegenerative and inflammatory markers measured in cerebrospinal fluid, including amyloid-β, tau, alpha-synuclein, and neurofilament light chain (optional, for participants who consent to lumbar puncture)
Time frame: assessed at Baseline Visit and Closeout Visit (after 18 months)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jun 2029, 41 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 41 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.